摘要
慢性阻塞性肺病（COPD）是一种进行性呼吸系统疾病，其特征在于不可逆的慢性炎症和气流阻塞。 它影响到全世界超过6400万患者，预计到2030年它将成为工业化国家的第三大死因。目前可用的治疗方法无法阻止疾病进展和降低死亡率，因此需要更好地了解COPD 确定新的分子治疗靶点的病理生理机制。 最近的研究表明，磷酸肌醇3-激酶（PI3K）信号在COPD中显着激活，并与患者对肺部感染的易感性增加相关。 因此，PI3K已成为COPD的有希望的替代药物靶标，并且已经在临床前模型中测试了多种泛同种型和同种型选择性抑制剂，并且目前正在临床研究中进行评估。 在这里，我们总结了最近关于PI3K酶参与COPD病理生理学的知识，并且我们讨论了PI3K抑制剂作为COPD新疗法的临床前和临床测试所产生的最新结果。
关键词: COPD，PI3K，炎症，靶向治疗，临床试验，P13K抑制剂。
[1]
Vetrano, D.L.; Foebel, A.D.; Marengoni, A.; Brandi, V.; Collamati, A.; Heckman, G.A.; Hirdes, J.; Bernabei, R.; Onder, G. Chronic diseases and geriatric syndromes: The different weight of comorbidity. Eur. J. Intern. Med., 2016, 27, 62-67. [http://dx.doi.org/10.1016/j.ejim.2015.10.025]. [PMID: 26643938].
[2]
Gross, N.J.; Barnes, P.J. New therapies for asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2017, 195(2), 159-166. [http://dx.doi.org/10.1164/rccm.201610-2074PP]. [PMID: 27922751].
[3]
Barnes, P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol., 2016, 138(1), 16-27. [http://dx.doi.org/10.1016/j.jaci.2016.05.011]. [PMID: 27373322].
[4]
Semenova, T.P.; Bragin, A.G.; Grishchenko, N.I.; Nesterova, I.V.; Vinogradova, O.S.; Gromova, E.A. Compensation for behavioral disorders due to administration of 6-hydroxy-dopamine in transplantation of embryonic locus coeruleus tissue in rats. Neurosci. Behav. Physiol., 1989, 19(5), 359-366. [http://dx.doi.org/10.1007/BF01197864]. [PMID: 2515469].
[5]
Decramer, M.; Janssens, W.; Miravitlles, M. Chronic obstructive pulmonary disease. Lancet, 2012, 379(9823), 1341-1351. [http://dx.doi.org/10.1016/S0140-6736(11)60968-9]. [PMID: 22314182].
[6]
Barnes, P.J. Identifying molecular targets for new drug development for chronic obstructive pulmonary disease: What does the future hold? Semin. Respir. Crit. Care Med., 2015, 36(4), 508-522. [http://dx.doi.org/10.1055/s-0035-1555611]. [PMID: 26238638].
[7]
Yoon, H.K.; Park, Y.B.; Rhee, C.K.; Lee, J.H.; Oh, Y.M. Summary of the chronic obstructive pulmonary disease clinical practice guideline revised in 2014 by the korean academy of tuberculosis and respiratory disease. Tuberc. Respir. Dis. (Seoul), 2017, 80(3), 230-240. [http://dx.doi.org/10.4046/trd.2017.80.3.230]. [PMID: 28747955].
[8]
Vogelmeier, C.F.; Criner, G.J.; Martinez, F.J.; Anzueto, A.; Barnes, P.J.; Bourbeau, J.; Celli, B.R.; Chen, R.; Decramer, M.; Fabbri, L.M.; Frith, P.; Halpin, D.M.; López Varela, M.V.; Nishimura, M.; Roche, N.; Rodriguez-Roisin, R.; Sin, D.D.; Singh, D.; Stockley, R.; Vestbo, J.; Wedzicha, J.A.; Agusti, A. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 Report: GOLD Executive Summary. Respirology, 2017, 22(3), 575-601. [http://dx.doi.org/10.1111/resp.13012]. [PMID: 28150362].
[9]
Rodrigo, G.J.; Price, D.; Anzueto, A.; Singh, D.; Altman, P.; Bader, G.; Patalano, F.; Fogel, R.; Kostikas, K. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis., 2017, 12, 907-922. [http://dx.doi.org/10.2147/COPD.S130482]. [PMID: 28360514].
[10]
Barnes, P.J.; Shapiro, S.D.; Pauwels, R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir. J., 2003, 22(4), 672-688. [http://dx.doi.org/10.1183/09031936.03.00040703]. [PMID: 14582923].
[11]
Ito, K.; Caramori, G.; Adcock, I.M. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J. Pharmacol. Exp. Ther., 2007, 321(1), 1-8. [http://dx.doi.org/10.1124/jpet.106.111674]. [PMID: 17021257].
[12]
Ito, K.; Ito, M.; Elliott, W.M.; Cosio, B.; Caramori, G.; Kon, O.M.; Barczyk, A.; Hayashi, S.; Adcock, I.M.; Hogg, J.C.; Barnes, P.J. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med., 2005, 352(19), 1967-1976. [http://dx.doi.org/10.1056/NEJMoa041892]. [PMID: 15888697].
[13]
Reuter, S.; Taube, C. Mast cells and the development of allergic airway disease. J. Occup. Med. Toxicol., 2008, 3(Suppl. 1), S2. [http://dx.doi.org/10.1186/1745-6673-3-S1-S2]. [PMID: 18315833].
[14]
Galli, S.J.; Nakae, S.; Tsai, M. Mast cells in the development of adaptive immune responses. Nat. Immunol., 2005, 6(2), 135-142. [http://dx.doi.org/10.1038/ni1158]. [PMID: 15662442].
[15]
Mortaz, E.; Folkerts, G.; Redegeld, F. Mast cells and COPD. Pulm. Pharmacol. Ther., 2011, 24(4), 367-372. [http://dx.doi.org/10.1016/j.pupt.2011.03.007]. [PMID: 21463700].
[16]
Kalesnikoff, J.; Galli, S.J. New developments in mast cell biology. Nat. Immunol., 2008, 9(11), 1215-1223. [http://dx.doi.org/10.1038/ni.f.216]. [PMID: 18936782].
[17]
Mortaz, E.; Givi, M.E.; Da Silva, C.A.; Folkerts, G.; Redegeld, F.A. A relation between TGF-β and mast cell tryptase in experimental emphysema models. Biochim. Biophys. Acta, 2012, 1822(7), 1154-1160. [http://dx.doi.org/10.1016/j.bbadis.2012.03.006]. [PMID: 22481124].
[18]
Thakurdas, S.M.; Melicoff, E.; Sansores-Garcia, L.; Moreira, D.C.; Petrova, Y.; Stevens, R.L.; Adachi, R. The mast cell-restricted tryptase mMCP-6 has a critical immunoprotective role in bacterial infections. J. Biol. Chem., 2007, 282(29), 20809-20815. [http://dx.doi.org/10.1074/jbc.M611842200]. [PMID: 17456473].
[19]
Kalenderian, R.; Raju, L.; Roth, W.; Schwartz, L.B.; Gruber, B.; Janoff, A. Elevated histamine and tryptase levels in smokers’ bronchoalveolar lavage fluid. Do lung mast cells contribute to smokers’ emphysema? Chest, 1988, 94(1), 119-123. [http://dx.doi.org/10.1378/chest.94.1.119]. [PMID: 2454780].
[20]
Wei, X.M.; Kim, H.S.; Kumar, R.K.; Heywood, G.J.; Hunt, J.E.; McNeil, H.P.; Thomas, P.S. Effects of cigarette smoke on degranulation and NO production by mast cells and epithelial cells. Respir. Res., 2005, 6, 108. [http://dx.doi.org/10.1186/1465-9921-6-108]. [PMID: 16168067].
[21]
Beckett, E.L.; Stevens, R.L.; Jarnicki, A.G.; Kim, R.Y.; Hanish, I.; Hansbro, N.G.; Deane, A.; Keely, S.; Horvat, J.C.; Yang, M.; Oliver, B.G.; van Rooijen, N.; Inman, M.D.; Adachi, R.; Soberman, R.J.; Hamadi, S.; Wark, P.A.; Foster, P.S.; Hansbro, P.M. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. J. Allergy Clin. Immunol., 2013, 131(3), 752-762. [http://dx.doi.org/10.1016/j.jaci.2012.11.053]. [PMID: 23380220].
[22]
van der Strate, B.W.; Postma, D.S.; Brandsma, C.A.; Melgert, B.N.; Luinge, M.A.; Geerlings, M.; Hylkema, M.N.; van den Berg, A.; Timens, W.; Kerstjens, H.A. Cigarette smoke-induced emphysema: A role for the B cell? Am. J. Respir. Crit. Care Med., 2006, 173(7), 751-758. [http://dx.doi.org/10.1164/rccm.200504-594OC]. [PMID: 16399994].
[23]
Hogg, J.C.; Chu, F.; Utokaparch, S.; Woods, R.; Elliott, W.M.; Buzatu, L.; Cherniack, R.M.; Rogers, R.M.; Sciurba, F.C.; Coxson, H.O.; Paré, P.D. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med., 2004, 350(26), 2645-2653. [http://dx.doi.org/10.1056/NEJMoa032158]. [PMID: 15215480].
[24]
Bracke, K.R.; Verhamme, F.M.; Seys, L.J.; Bantsimba-Malanda, C.; Cunoosamy, D.M.; Herbst, R.; Hammad, H.; Lambrecht, B.N.; Joos, G.F.; Brusselle, G.G. Role of CXCL13 in cigarette smoke-induced lymphoid follicle formation and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2013, 188(3), 343-355. [http://dx.doi.org/10.1164/rccm.201211-2055OC]. [PMID: 23742729].
[25]
Feghali-Bostwick, C.A.; Gadgil, A.S.; Otterbein, L.E.; Pilewski, J.M.; Stoner, M.W.; Csizmadia, E.; Zhang, Y.; Sciurba, F.C.; Duncan, S.R. Autoantibodies in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2008, 177(2), 156-163. [http://dx.doi.org/10.1164/rccm.200701-014OC]. [PMID: 17975205].
[26]
Kirkham, P.A.; Caramori, G.; Casolari, P.; Papi, A.A.; Edwards, M.; Shamji, B.; Triantaphyllopoulos, K.; Hussain, F.; Pinart, M.; Khan, Y.; Heinemann, L.; Stevens, L.; Yeadon, M.; Barnes, P.J.; Chung, K.F.; Adcock, I.M. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2011, 184(7), 796-802. [http://dx.doi.org/10.1164/rccm.201010-1605OC]. [PMID: 21965015].
[27]
Ghigo, A.; Damilano, F.; Braccini, L.; Hirsch, E. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. BioEssays, 2010, 32(3), 185-196. [http://dx.doi.org/10.1002/bies.200900150]. [PMID: 20162662].
[28]
Medina-Tato, D.A.; Ward, S.G.; Watson, M.L. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology, 2007, 121(4), 448-461. [http://dx.doi.org/10.1111/j.1365-2567.2007.02663.x]. [PMID: 17614878].
[29]
Domin, J.; Waterfield, M.D. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett., 1997, 410(1), 91-95. [http://dx.doi.org/10.1016/S0014-5793(97)00617-0]. [PMID: 9247130].
[30]
Wymann, M.P.; Zvelebil, M.; Laffargue, M. Phosphoinositide 3-kinase signalling--which way to target? Trends Pharmacol. Sci., 2003, 24(7), 366-376. [http://dx.doi.org/10.1016/S0165-6147(03)00163-9]. [PMID: 12871670].
[31]
Ciraolo, E.; Iezzi, M.; Marone, R.; Marengo, S.; Curcio, C.; Costa, C.; Azzolino, O.; Gonella, C.; Rubinetto, C.; Wu, H.; Dastrù, W.; Martin, E.L.; Silengo, L.; Altruda, F.; Turco, E.; Lanzetti, L.; Musiani, P.; Rückle, T.; Rommel, C.; Backer, J.M.; Forni, G.; Wymann, M.P.; Hirsch, E. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal., 2008, 1(36), ra3. [http://dx.doi.org/10.1126/scisignal.1161577]. [PMID: 18780892].
[32]
Fischer, M.; Bockhorst, K.; Hoehn-Berlage, M.; Schmitz, B.; Hossmann, K.A. Imaging of the apparent diffusion coefficient for the evaluation of cerebral metabolic recovery after cardiac arrest. Magn. Reson. Imaging, 1995, 13(6), 781-790. [http://dx.doi.org/10.1016/0730-725X(95)00030-K]. [PMID: 8544649].
[33]
Schmid, M.C.; Avraamides, C.J.; Dippold, H.C.; Franco, I.; Foubert, P.; Ellies, L.G.; Acevedo, L.M.; Manglicmot, J.R.; Song, X.; Wrasidlo, W.; Blair, S.L.; Ginsberg, M.H.; Cheresh, D.A.; Hirsch, E.; Field, S.J.; Varner, J.A. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell, 2011, 19(6), 715-727. [http://dx.doi.org/10.1016/j.ccr.2011.04.016]. [PMID: 21665146].
[34]
Freund, G.G.; Wittig, J.G.; Mooney, R.A. The PI3-kinase serine kinase phosphorylates its p85 subunit and IRS-1 in PI3-kinase/IRS-1 complexes. Biochem. Biophys. Res. Commun., 1995, 206(1), 272-278. [http://dx.doi.org/10.1006/bbrc.1995.1038]. [PMID: 7818531].
[35]
Vanhaesebroeck, B.; Guillermet-Guibert, J.; Graupera, M.; Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol., 2010, 11(5), 329-341. [http://dx.doi.org/10.1038/nrm2882]. [PMID: 20379207].
[36]
Okkenhaug, K.; Bilancio, A.; Farjot, G.; Priddle, H.; Sancho, S.; Peskett, E.; Pearce, W.; Meek, S.E.; Salpekar, A.; Waterfield, M.D.; Smith, A.J.; Vanhaesebroeck, B. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science, 2002, 297(5583), 1031-1034. [http://dx.doi.org/10.1126/science.1073560]. [PMID: 12130661].
[37]
Hirsch, E.; Katanaev, V.L.; Garlanda, C.; Azzolino, O.; Pirola, L.; Silengo, L.; Sozzani, S.; Mantovani, A.; Altruda, F.; Wymann, M.P. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science, 2000, 287(5455), 1049-1053. [http://dx.doi.org/10.1126/science.287.5455.1049]. [PMID: 10669418].
[38]
Sadhu, C.; Masinovsky, B.; Dick, K.; Sowell, C.G.; Staunton, D.E. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J. Immunol., 2003, 170(5), 2647-2654. [http://dx.doi.org/10.4049/jimmunol.170.5.2647]. [PMID: 12594293].
[39]
Ferreira, A.M.; Isaacs, H.; Hayflick, J.S.; Rogers, K.A.; Sandig, M. The p110delta isoform of PI3K differentially regulates beta1 and beta2 integrin-mediated monocyte adhesion and spreading and modulates diapedesis. Microcirculation, 2006, 13(6), 439-456. [http://dx.doi.org/10.1080/10739680600776062]. [PMID: 16864411].
[40]
Tkaczyk, C.; Beaven, M.A.; Brachman, S.M.; Metcalfe, D.D.; Gilfillan, A.M. The phospholipase C gamma 1-dependent pathway of Fc epsilon RI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase. J. Biol. Chem., 2003, 278(48), 48474-48484. [http://dx.doi.org/10.1074/jbc.M301350200]. [PMID: 13129935].
[41]
Ali, K.; Bilancio, A.; Thomas, M.; Pearce, W.; Gilfillan, A.M.; Tkaczyk, C.; Kuehn, N.; Gray, A.; Giddings, J.; Peskett, E.; Fox, R.; Bruce, I.; Walker, C.; Sawyer, C.; Okkenhaug, K.; Finan, P.; Vanhaesebroeck, B. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature, 2004, 431(7011), 1007-1011. [http://dx.doi.org/10.1038/nature02991]. [PMID: 15496927].
[42]
Ali, K.; Camps, M.; Pearce, W.P.; Ji, H.; Rückle, T.; Kuehn, N.; Pasquali, C.; Chabert, C.; Rommel, C.; Vanhaesebroeck, B. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J. Immunol., 2008, 180(4), 2538-2544. [http://dx.doi.org/10.4049/jimmunol.180.4.2538]. [PMID: 18250464].
[43]
Laffargue, M.; Calvez, R.; Finan, P.; Trifilieff, A.; Barbier, M.; Altruda, F.; Hirsch, E.; Wymann, M.P. Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity, 2002, 16(3), 441-451. [http://dx.doi.org/10.1016/S1074-7613(02)00282-0]. [PMID: 11911828].
[44]
Yanagisawa, S.; Baker, J.R.; Vuppusetty, C.; Fenwick, P.; Donnelly, L.E.; Ito, K.; Barnes, P.J. Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD. Am. J. Physiol. Lung Cell. Mol. Physiol., 2017, 313(2), L230-L239. [http://dx.doi.org/10.1152/ajplung.00382.2016]. [PMID: 28522564].
[45]
Liu, A.; Wu, J.; Li, A.; Bi, W.; Liu, T.; Cao, L.; Liu, Y.; Dong, L. The inhibitory mechanism of Cordyceps sinensis on cigarette smoke extract-induced senescence in human bronchial epithelial cells. Int. J. Chron. Obstruct. Pulmon. Dis., 2016, 11, 1721-1731. [http://dx.doi.org/10.2147/COPD.S107396]. [PMID: 27555762].
[46]
Baker, J.R.; Vuppusetty, C.; Colley, T.; Papaioannou, A.I.; Fenwick, P.; Donnelly, L.; Ito, K.; Barnes, P.J. Oxidative stress dependent microRNA-34a activation via PI3Kα reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells. Sci. Rep., 2016, 6, 35871. [http://dx.doi.org/10.1038/srep35871]. [PMID: 27767101].
[47]
Hsu, A.C.; Starkey, M.R.; Hanish, I.; Parsons, K.; Haw, T.J.; Howland, L.J.; Barr, I.; Mahony, J.B.; Foster, P.S.; Knight, D.A.; Wark, P.A.; Hansbro, P.M. Targeting PI3K-p110α suppresses influenza virus infection in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2015, 191(9), 1012-1023. [http://dx.doi.org/10.1164/rccm.201501-0188OC]. [PMID: 25751541].
[48]
Gustafson, A.M.; Soldi, R.; Anderlind, C.; Scholand, M.B.; Qian, J.; Zhang, X.; Cooper, K.; Walker, D.; McWilliams, A.; Liu, G.; Szabo, E.; Brody, J.; Massion, P.P.; Lenburg, M.E.; Lam, S.; Bild, A.H.; Spira, A. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci. Transl. Med., 2010, 2(26)26ra25 [http://dx.doi.org/10.1126/scitranslmed.3000251]. [PMID: 20375364].
[49]
Angulo, I.; Vadas, O.; Garçon, F.; Banham-Hall, E.; Plagnol, V.; Leahy, T.R.; Baxendale, H.; Coulter, T.; Curtis, J.; Wu, C.; Blake-Palmer, K.; Perisic, O.; Smyth, D.; Maes, M.; Fiddler, C.; Juss, J.; Cilliers, D.; Markelj, G.; Chandra, A.; Farmer, G.; Kielkowska, A.; Clark, J.; Kracker, S.; Debré, M.; Picard, C.; Pellier, I.; Jabado, N.; Morris, J.A.; Barcenas-Morales, G.; Fischer, A.; Stephens, L.; Hawkins, P.; Barrett, J.C.; Abinun, M.; Clatworthy, M.; Durandy, A.; Doffinger, R.; Chilvers, E.R.; Cant, A.J.; Kumararatne, D.; Okkenhaug, K.; Williams, R.L.; Condliffe, A.; Nejentsev, S. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science, 2013, 342(6160), 866-871. [http://dx.doi.org/10.1126/science.1243292]. [PMID: 24136356].
[50]
Gao, X.P.; Zhu, X.; Fu, J.; Liu, Q.; Frey, R.S.; Malik, A.B. Blockade of class IA phosphoinositide 3-kinase in neutrophils prevents NADPH oxidase activation- and adhesion-dependent inflammation. J. Biol. Chem., 2007, 282(9), 6116-6125. [http://dx.doi.org/10.1074/jbc.M610248200]. [PMID: 17197441].
[51]
Thomas, M.J.; Smith, A.; Head, D.H.; Milne, L.; Nicholls, A.; Pearce, W.; Vanhaesebroeck, B.; Wymann, M.P.; Hirsch, E.; Trifilieff, A.; Walker, C.; Finan, P.; Westwick, J. Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur. J. Immunol., 2005, 35(4), 1283-1291. [http://dx.doi.org/10.1002/eji.200425634]. [PMID: 15739165].
[52]
Jones, G.E.; Prigmore, E.; Calvez, R.; Hogan, C.; Dunn, G.A.; Hirsch, E.; Wymann, M.P.; Ridley, A.J. Requirement for PI 3-kinase gamma in macrophage migration to MCP-1 and CSF-1. Exp. Cell Res., 2003, 290(1), 120-131. [http://dx.doi.org/10.1016/S0014-4827(03)00318-5]. [PMID: 14516793].
[53]
Bonnans, C.; Fukunaga, K.; Keledjian, R.; Petasis, N.A.; Levy, B.D. Regulation of phosphatidylinositol 3-kinase by polyisoprenyl phosphates in neutrophil-mediated tissue injury. J. Exp. Med., 2006, 203(4), 857-863. [http://dx.doi.org/10.1084/jem.20052143]. [PMID: 16567384].
[54]
Yum, H.K.; Arcaroli, J.; Kupfner, J.; Shenkar, R.; Penninger, J.M.; Sasaki, T.; Yang, K.Y.; Park, J.S.; Abraham, E. Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury. J. Immunol., 2001, 167(11), 6601-6608. [http://dx.doi.org/10.4049/jimmunol.167.11.6601]. [PMID: 11714830].
[55]
Doukas, J.; Eide, L.; Stebbins, K.; Racanelli-Layton, A.; Dellamary, L.; Martin, M.; Dneprovskaia, E.; Noronha, G.; Soll, R.; Wrasidlo, W.; Acevedo, L.M.; Cheresh, D.A. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther., 2009, 328(3), 758-765. [http://dx.doi.org/10.1124/jpet.108.144311]. [PMID: 19056934].
[56]
Ghorani, V.; Boskabady, M.H.; Khazdair, M.R.; Kianmeher, M. Experimental animal models for COPD: a methodological review. Tob. Induc. Dis., 2017, 15, 25. [http://dx.doi.org/10.1186/s12971-017-0130-2]. [PMID: 28469539].
[57]
Wright, J.L.; Cosio, M.; Churg, A. Animal models of chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol. Physiol., 2008, 295(1), L1-L15. [http://dx.doi.org/10.1152/ajplung.90200.2008]. [PMID: 18456796].
[58]
Galluzzo, M.; Ciraolo, E.; Lucattelli, M.; Hoxha, E.; Ulrich, M.; Campa, C.C.; Lungarella, G.; Doring, G.; Zhou-Suckow, Z.; Mall, M.; Hirsch, E.; De Rose, V. Genetic deletion and pharmacological inhibition of PI3K γ reduces neutrophilic airway inflammation and lung damage in mice with Cystic Fibrosis-Like Lung Disease. Mediators Inflamm., 2015, 2015545417 [http://dx.doi.org/10.1155/2015/545417]. [PMID: 26185363].
[59]
Norman, P. Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729. Expert Opin. Ther. Pat., 2014, 24(4), 471-475. [http://dx.doi.org/10.1517/13543776.2014.865725]. [PMID: 24283201].
[60]
Marwick, J.A.; Caramori, G.; Casolari, P.; Mazzoni, F.; Kirkham, P.A.; Adcock, I.M.; Chung, K.F.; Papi, A. A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol., 2010, 125(5), 1146-1153. [http://dx.doi.org/10.1016/j.jaci.2010.02.003]. [PMID: 20381852].
[61]
Marwick, J.A.; Caramori, G.; Stevenson, C.S.; Casolari, P.; Jazrawi, E.; Barnes, P.J.; Ito, K.; Adcock, I.M.; Kirkham, P.A.; Papi, A. Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am. J. Respir. Crit. Care Med., 2009, 179(7), 542-548. [http://dx.doi.org/10.1164/rccm.200810-1570OC]. [PMID: 19164702].
[62]
To, Y.; Ito, K.; Kizawa, Y.; Failla, M.; Ito, M.; Kusama, T.; Elliott, W.M.; Hogg, J.C.; Adcock, I.M.; Barnes, P.J. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2010, 182(7), 897-904. [http://dx.doi.org/10.1164/rccm.200906-0937OC]. [PMID: 20224070].
[63]
Horiguchi, M.; Oiso, Y.; Sakai, H.; Motomura, T.; Yamashita, C. Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration. J. Control. Release, 2015, 213, 112-119. [http://dx.doi.org/10.1016/j.jconrel.2015.07.004]. [PMID: 26160307].
[64]
Cahn, A.; Hamblin, J.N.; Begg, M.; Wilson, R.; Dunsire, L.; Sriskantharajah, S.; Montembault, M.; Leemereise, C.N.; Galinanes-Garcia, L.; Watz, H.; Kirsten, A.M.; Fuhr, R.; Hessel, E.M. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. Pulm. Pharmacol. Ther., 2017, 46, 69-77. [http://dx.doi.org/10.1016/j.pupt.2017.08.008]. [PMID: 28823947].
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
63
6
3
1